Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG39001

DMTN Knockout Raji Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone

  • Disease:

    Burkitt lymphoma

DMTN Knockout Raji Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population in a human B-lymphocyte line. This model disrupts dematin, an actin-bundling protein that crosslinks actin and stabilizes the spectrin?Cactin membrane skeleton. Loss of DMTN alters cytoskeletal dynamics downstream of RhoA, Rac1, and Src family kinases, and is relevant to B-cell signaling and lymphoma research. Key applications include probing actin organization, membrane deformability, and immune synapse function via immunofluorescence, migration assays, and atomic force microscopy. The polyclonal format enables heterogeneous knockout studies without clonal artifacts.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Raji

    Cell Type

    B cell line

    Sex of Donor

    Male

    Age

    11 years

    Derived From Site

    In situ; Maxilla

    Gene Name

    DMTN

    Gene Identifier

    NCBI Gene ID 2039

    Morphology

    Lymphoblast-like

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

DMTN Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population with targeted disruption of the human DMTN gene in Raji B lymphocytes. This pool of gene-edited cells avoids clonal selection, preserving editing-outcome diversity for functional studies. DMTN encodes dematin, an actin-bundling protein essential for membrane-cytoskeletal linkage. The knockout model enables investigation of cytoskeletal dynamics and signaling in a B-cell context.

The Raji parental line originates from an EBV-positive Burkitt lymphoma and represents a classic B-lymphocyte model. These suspension cells are capable of antibody production, antigen presentation, and immune memory functions. Their lymphomagenic background, driven by MYC deregulation, provides a relevant system to study how DMTN loss impacts B-cell transformation and cytoskeletal integrity.

Dematin, the product of DMTN, crosslinks actin filaments and anchors the spectrin?Cactin junctional complex to the membrane. Its regulation involves integrin signaling, RhoA, Rac1, Abl kinase, and Src family kinases. Downstream, it stabilizes the spectrin network and influences membrane deformability. Key binding partners include spectrin, actin, adducin, tropomyosin, tropomodulin, and protein 4.1. Loss of dematin is predicted to disrupt RhoA/ROCK-mediated contractility and actin polymerization, compromising cytoskeletal organization and cell shape.

In B lymphocytes, DMTN knockout impacts immune synapse formation, antigen gathering, and migration by altering actin dynamics and membrane mechanics. This model facilitates dissection of cytoskeletal contributions to Burkitt lymphoma pathogenesis and can mirror hereditary elliptocytosis defects. The polyclonal design also permits analysis of response heterogeneity across the population.

Researchers can employ these cells in Western blotting for dematin, immunofluorescence for F-actin, and actin polymerization assays. Flow cytometry assesses morphology, transwell assays evaluate migration, and co-immunoprecipitation confirms spectrin interactions. Atomic force microscopy quantifies membrane stiffness. Applications include B-cell cytoskeleton studies, signaling pathway mapping, and drug target validation. For additional information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)